Table 2.
Clinical and mycological efficacy of nystatin and the control treatments
| Author | Risk factor | Clinical cure rate
|
Mycological cure rate
|
||||
|---|---|---|---|---|---|---|---|
| Nystatin (%) | Control (%) | OR (95% CI) | Nystatin (%) | Control (%) | OR (95% CI) | ||
| Mima et al26 | Denture | 53 | 45 | 1.22 (0.35–4.24) | – | – | – |
| Johnson et al27 | Denture | 28.6 | 0 | 7.73 (0.31–193.44) | 57.1 | 0 | 21.86 (0.91–523.42) |
| 14.3 | 0 | 3.92 (0.14–112.90) | 71.4 | 0 | 37.40 (1.49–936.27) | ||
| Nairn28 | Denture | 76.9 | 88.8 | 0.42 (0.06–2.95) | 40 | 6.25 | 10.00 (0.92–108.82) |
| 76.9 | 40 | 5.00 (0.96–26.11) | 40 | 20 | 2.67 (0.36–19.71) | ||
| Goins et al29 | Infants | 28.6 | 100 | 0.01 (0.00–0.26) | 5.6 | 73.3 | 0.07 (0.01–0.64) |
| Hoppe20 | Infants | 54.1 | 99 | 0.01 (0.00–0.09) | 8.2 | 54.1 | 0.08 (0.03–0.18) |
| Flynn et al30 | Infants and children | 51 | 91 | 0.11 (0.04–0.25) | 11 | 76 | 0.04 (0.01–0.11) |
| Moshi et al31 | AIDS | 63.5 | 55.6 | 1.24 (0.65–2.37) | – | – | – |
| Pons et al32 | HIV/AIDS | 52 | 87 | 0.16 (0.07–0.38) | 6 | 60 | 0.04 (0.01–0.13) |
| Nyst et al33 | AIDS | 9 | 42 | 0.13 (0.03–0.67) | 13 | 62 | 0.09 (0.02–0.40) |
| 9 | 43 | 0.12 (0.02–0.66) | 13 | 57 | 0.12 (0.03–0.50) | ||
| Meunier et al34 | Cancer patients | 87.5 | 72.2 | 2.69 (0.55–13.20) | 66 | 61 | 1.27 (0.36–4.54) |
| Blomgren et al35 | Multigroup patients | 16.7 | 30 | 0.47 (0.14–1.61) | – | – | – |
Abbreviations: CI, confidence interval; OR, odds ratio.